v3.26.1
Summary of Significant Accounting Policies (Details Narrative)
1 Months Ended 12 Months Ended
Sep. 11, 2025
USD ($)
$ / shares
shares
Sep. 05, 2025
USD ($)
Jun. 03, 2025
USD ($)
Mar. 01, 2024
USD ($)
Dec. 31, 2025
USD ($)
$ / shares
shares
Feb. 29, 2024
USD ($)
$ / shares
shares
Dec. 31, 2025
USD ($)
$ / shares
shares
Dec. 31, 2024
USD ($)
$ / shares
shares
Dec. 31, 2025
AUD ($)
shares
Jul. 25, 2024
USD ($)
Dec. 31, 2023
$ / shares
SignificantAccountingPoliciesLineItems [Line Items]                      
Net loss             $ 29,438,613 $ 21,613,376      
Accumulated deficit         $ 104,463,284   $ 104,463,284 $ 75,024,671      
Stock option granted | shares             1,394,440 1,572,176      
Grants receivable on reimbursement         4,600,000   $ 4,600,000     $ 8,000,000  
Grants receivable             2,800,000 $ 1,900,000      
Grants receivable based on achievement of milestones         $ 3,400,000   3,400,000        
Shares issued value             $ 93,689,681 $ 15,520,354      
Common stock, par value | $ / shares         $ 0.0001   $ 0.0001 $ 0.0001      
Exercise price | $ / shares         1.32   1.32 $ 0.71     $ 0.71
Share price | $ / shares         $ 5.10   $ 5.10        
Cash and cash equivalents and short term invesrments         $ 100,400,000   $ 100,400,000        
FDIC insured amount         250,000   250,000   $ 250,000    
Short-Term Investments         6,480,860   6,480,860      
Research and development expense             16,258,598 11,292,702      
Income Taxes Receivable           1,974,370      
Deferred offering costs         $ 93,630   93,630        
Foreign currency transaction gains and losses             $ (20,284) $ (39,600)      
Stock Options and Warrants Exercisable [Member]                      
SignificantAccountingPoliciesLineItems [Line Items]                      
Antidilutive securities excluded from computation of earnings per share, amount | shares             8,442,317 4,463,488      
Australian Tax Incentive [Member]                      
SignificantAccountingPoliciesLineItems [Line Items]                      
Research and development expense             $ 806 $ 1,299,616      
June 2025 ATM Agreement [Member]                      
SignificantAccountingPoliciesLineItems [Line Items]                      
Shares issued value     $ 50,000,000                
Number of shares sold | shares             1,697,504        
Net proceeds of common stock             $ 4,409,430        
Securities Purchase Agreements [Member]                      
SignificantAccountingPoliciesLineItems [Line Items]                      
Common stock, par value | $ / shares $ 0.0001                    
Exercise price | $ / shares $ 2.37                    
Proceeds from private placement $ 9,300,000 $ 9,300,000                  
Share price | $ / shares $ 2.00                    
Common Stock [Member]                      
SignificantAccountingPoliciesLineItems [Line Items]                      
Number of shares sold in public offering | shares         19,117,646 5,535,055          
Exercise price, per share | $ / shares           $ 2.71          
Underwriter discounts and offering expenses       $ 1,954,594   $ 13,565,760          
Stock option granted | shares           783,970          
Shares issued value             $ 1,911 $ 632      
Common Stock [Member] | Prefunded Warrants [Member]                      
SignificantAccountingPoliciesLineItems [Line Items]                      
Exercise price, per share | $ / shares         $ 0.01   $ 0.01        
Underlying pre-funded warrants | shares             2,403,857 1,913,661      
Common Stock [Member] | Securities Purchase Agreements [Member]                      
SignificantAccountingPoliciesLineItems [Line Items]                      
Issuance of shares | shares 3,915,604                    
Warrant [Member]                      
SignificantAccountingPoliciesLineItems [Line Items]                      
Issuance of warrants | shares 2,936,709                    
Pre Funded Warrant [Member]                      
SignificantAccountingPoliciesLineItems [Line Items]                      
Exercise price, per share | $ / shares         $ 5.09   $ 5.09        
Net proceeds of common stock             $ 93,700,000        
Shares issued | shares         490,196   490,196   490,196    
Immix Biopharma Australia Pty Ltd. [Member]                      
SignificantAccountingPoliciesLineItems [Line Items]                      
Non-controlling interest rate         100.00%   100.00%   100.00%